Aleksandr Ianevski
Overview
Explore the profile of Aleksandr Ianevski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravlo E, Ianevski A, Schjolberg J, Solvang V, Dumaru R, Lysvand H, et al.
Cell Mol Life Sci
. 2025 Jan;
82(1):57.
PMID: 39843710
Enteroviruses can infect various human organs, causing diseases such as meningitis, the common cold, hand-foot-and-mouth disease, myocarditis, pancreatitis, hepatitis, poliomyelitis, sepsis, and type 1 diabetes. Currently, there are no approved...
2.
Kainov D, Ravlo E, Ianevski A
Antiviral Res
. 2025 Jan;
234():106079.
PMID: 39798882
Antiviral drugs are crucial for managing viral infections, but current treatment options remain limited, particularly for emerging viruses. These drugs can be classified based on their chemical composition, including neutralizing...
3.
Nygren P, Bouhlal J, Jokinen E, Forsten S, Laajala E, Dias D, et al.
Blood
. 2025 Jan;
PMID: 39792962
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK cell function with oncological drugs could...
4.
Poloske D, Sorger H, Schonbichler A, de Araujo E, Neubauer H, Orlova A, et al.
Hemasphere
. 2024 Dec;
8(12):e70001.
PMID: 39619245
The transcription factors STAT3, STAT5A, and STAT5B steer hematopoiesis and immunity, but their enhanced expression and activation promote acute myeloid leukemia (AML) or natural killer/T cell lymphoma (NKCL). Current therapeutic...
5.
Andersen G, Ianevski A, Resell M, Pojskic N, Rabben H, Geithus S, et al.
NPJ Syst Biol Appl
. 2024 Nov;
10(1):127.
PMID: 39496635
Biomarkers associated with the progression from gastric intestinal metaplasia (GIM) to gastric adenocarcinoma (GA), i.e., GA-related GIM, could provide valuable insights into identifying patients with increased risk for GA. The...
6.
Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, et al.
Nat Commun
. 2024 Oct;
15(1):8579.
PMID: 39362905
Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell populations poses a combinatorial challenge, since...
7.
Ianevski A, Kushnir A, Nader K, Miihkinen M, Xhaard H, Aittokallio T, et al.
Brief Bioinform
. 2024 Jul;
25(4).
PMID: 38980370
RepurposeDrugs (https://repurposedrugs.org/) is a comprehensive web-portal that combines a unique drug indication database with a machine learning (ML) predictor to discover new drug-indication associations for approved as well as investigational...
8.
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, et al.
Blood
. 2024 Jun;
144(15):1595-1610.
PMID: 38941598
T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with marked chemotherapy resistance and continued poor clinical outcomes. Current treatments, that is, the CD52-antibody alemtuzumab, offer transient responses, with relapses...
9.
Nader K, Tasci M, Ianevski A, Erickson A, Verschuren E, Aittokallio T, et al.
Bioinformatics
. 2024 Jun;
40(7).
PMID: 38936341
Summary: The limited resolution of spatial transcriptomics (ST) assays in the past has led to the development of cell type annotation methods that separate the convolved signal based on available...
10.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, et al.
Cell Rep Med
. 2024 Apr;
5(5):101521.
PMID: 38653245
BCR::ABL1-independent pathways contribute to primary resistance to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in leukemic stem cell persistence. Here, we perform ex ...